Completed PHASE2 INTERVENTIONAL 4-arm NCT03016143

Immunogenicity and Safety Study of Allantoic Split Inactivated Seasonal Influenza Vaccine (VSI)

A Randomized, Blinded, Comparative Study of Phase II Allantoic Split Inactivated Seasonal Influenza Vaccine in Healthy Adults

Sponsor: Asfendiyarov Kazakh National Medical University

Conditions Influenza

Interventions Allantoic Split Inactivated Seasonal flu Vaccine VAXIGRIP

Updated 7 times since 2017 Last updated: Jun 6, 2018 Started: Oct 31, 2016 Primary completion: Nov 30, 2016 Completion: Dec 31, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Influenza and is currently completed. Asfendiyarov Kazakh National Medical University leads this study, which shows 7 recorded versions since 2016 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Oct 2018 — Jan 2021 [monthly]

Completed PHASE2
Jul 2018 — Oct 2018 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Jun 2018 — Jul 2018 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Oct 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Asfendiyarov Kazakh National Medical University
Research Institute for Biological Safety Problems
Research Institute of Influenza, Russia

Data source: Research Institute for Biological Safety Problems

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Almaty, Kazakhstan